Abstract
An essential step in the big picture of science in medicine is to transform the new and groundbreaking findings established in a laboratory into clinical applications that are available to patients in everyday life. The science that deals with this issue is called translational medicine and focuses, among other things, on “translating” research findings into clinical applications as well as clinical problems into research experiments. While these processes seem very straightforward, they have been identified as the most crucial bottleneck in the development and provision of new therapies. This chapter explains what translational medicine is, why we need it, and several ways in which it can be accomplished.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Lean MEJ, Mann JI, Hoek JA, Elliot RM, Schofield G. Translational research. BMJ. 2008;337:a863.
Ioannidis JP. Materializing research promises: opportunities, priorities and conflicts in translational medicine. J Transl Med. 2004;2(1):5.
Marincola FM. Translational medicine: a two-way road. J Transl Med. 2003;1(1):1.
Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn’t. BMJ. 1996;312(7023):71–2.
Sackett DL, Strauss S, Ricahrdson W, Haynes B. Evidence based medicine: how to practice and teach EBM. 2nd ed. London: Churchill Livingston; 2000.
Habashi JP, Doyle JJ, Holm TM, et al. Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science. 2011;332(6027):361–5.
Holm TM, Habashi JP, Doyle JJ, et al. Noncanonical TGF-beta signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science. 2011;332(6027):358–61.
Beauchet O, Fantino B, Annweiler C. The ‘action-research’ philosophy: from bedside to bench, to bedside again. Int J Clin Pract. 2012;66(5):517.
Blumenthal D. Reverse translation in health policy and management: from bedside to bench and beyond. Health Serv Res. 2005;40(1):9–18.
Gold MS. From bedside to bench and back again: a 30-year saga. Physiol Behav. 2011;104(1):157–61.
Ablin RJ, Marincola FM, Natali PG. The “excellence in translational medicine” and “bedside-to-bench” awards 2008–09. J Transl Med. 2010;8:95.
Ablin RJ, Marincola FM, Natali PG. The “excellence in translational medicine” and “bedside-to-bench” awards 2007–08. J Transl Med. 2009;7:57.
Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2007 – an update. J Gene Med. 2007;9(10):833–42.
Edelstein ML, Abedi MR, Wixon J, Edelstein RM. Gene therapy clinical trials worldwide 1989–2004-an overview. J Gene Med. 2004;6(6):597–602.
Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther. 2005;16(9):1016–27.
Stolberg SG. The biotech death of Jesse Gelsinger. N Y Times Mag. 1999;136–140:149–50.
Wilson RF. The death of Jesse Gelsinger: new evidence of the influence of money and prestige in human research. Am J Law Med. 2010;36(2–3):295–325.
Smith L, Byers JF. Gene therapy in the post-Gelsinger era. JONAS Healthc Law Ethics Regul. 2002;4(4):104–10.
Caplan AI. Review: mesenchymal stem cells: cell-based reconstructive therapy in orthopedics. Tissue Eng. 2005;11(7–8):1198–211.
Schmitt A, van Griensven M, Imhoff AB, Buchmann S. Application of stem cells in orthopedics. Stem Cells Int. 2012;2012:394962.
Langer R, Vacanti JP. Tissue engineering. Science. 1993;260(5110):920–6.
Vavken P, Samartzis D. Effectiveness of autologous chondrocyte implantation in cartilage repair of the knee: a systematic review of controlled trials. Osteoarthritis Cartilage. 2010;18(6):857–63.
Sung NS, Crowley Jr WF, Genel M, et al. Central challenges facing the national clinical research enterprise. JAMA. 2003;289(10):1278–87.
Liang MH. Translational research: getting the word and the meaning right. Arthritis Care Res. 2003;49(5):720–1.
Barlas S. Critics assail FDA medical device approval process: slow review time and safety are at issue. P T. 2011;36(7):395–409.
Buch B. FDA medical device approval: things you didn’t learn in medical school or residency. Am J Orthop (Belle Mead NJ). 2007;36(8):407–12.
Lipsky MS, Sharp LK. From idea to market: the drug approval process. J Am Board Fam Pract. 2001;14(5):362–7.
Evans CH, Ghivizzani SC, Robbins PD. Orthopedic gene therapy – lost in translation? J Cell Physiol. 2011;227(2):416–20.
Acknowledgement
Research reported in this chapter was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Numbers RO1-AR047910 and RO1-AR054099. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Vavken, P. (2013). Translational Medicine. In: Murray, M., Vavken, P., Fleming, B. (eds) The ACL Handbook. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-0760-7_9
Download citation
DOI: https://doi.org/10.1007/978-1-4614-0760-7_9
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-0759-1
Online ISBN: 978-1-4614-0760-7
eBook Packages: MedicineMedicine (R0)